LLY241213P830000
- 40.59
- -8.15-16.72%
Eli Lilly and Co Newsroom
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,050
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $997
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $997
Eli Lilly Analyst Ratings
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Eli Lilly & Co (LLY) Gets a Buy From Jefferies
Erste Group Downgrades Eli Lilly and Co(LLY.US) to Hold Rating
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
The Trader: Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barron's
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barrons.com
Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,010
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $975
Barclays Keeps Their Buy Rating on Eli Lilly & Co (LLY)
Wolfe Research Initiates Coverage On Eli Lilly With Outperform Rating, Announces Price Target of $1000
Eli Lilly Analyst Ratings
Wolfe Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,000